PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-2.85%
Negative revenue growth while Medical - Pharmaceuticals median is 1.27%. Seth Klarman would investigate if the company is losing market share or facing a declining industry.
-2.33%
Negative gross profit growth while Medical - Pharmaceuticals median is 1.47%. Seth Klarman would suspect poor product pricing or inefficient production.
-21.34%
Negative EBIT growth while Medical - Pharmaceuticals median is 0.96%. Seth Klarman would check if external or internal factors caused the decline.
-23.85%
Negative operating income growth while Medical - Pharmaceuticals median is 0.96%. Seth Klarman would check if structural or cyclical issues are at play.
-21.96%
Negative net income growth while Medical - Pharmaceuticals median is 4.90%. Seth Klarman would investigate factors dragging net income down.
-22.00%
Negative EPS growth while Medical - Pharmaceuticals median is 5.95%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-22.00%
Negative diluted EPS growth while Medical - Pharmaceuticals median is 5.72%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
0.06%
Share growth above Medical - Pharmaceuticals median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
0.06%
Diluted share growth above 2x Medical - Pharmaceuticals median. Jim Chanos would suspect undue issuance or heavy employee stock compensation.
No Data
No Data available this quarter, please select a different quarter.
5.15%
OCF growth 50-75% of Medical - Pharmaceuticals median of 6.96%. Guy Spier would see subpar cash conversion vs. peers.
5.15%
FCF growth near Medical - Pharmaceuticals median of 5.15%. Charlie Munger could consider this standard for the industry’s capex cycle.
170.42%
10Y revenue/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 50.23%. Joel Greenblatt would verify if a unique moat or brand fosters outperformance over a decade.
62.00%
5Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 21.29%. Joel Greenblatt would see if the company’s moat drives rapid mid-term expansion.
34.07%
3Y revenue/share growth exceeding 1.5x Medical - Pharmaceuticals median of 21.46%. Joel Greenblatt might see a short-term competitive advantage at play.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
99.06%
Net income/share CAGR exceeding 1.5x Medical - Pharmaceuticals median of 39.04% over a decade. Joel Greenblatt might see a standout compounder of earnings.
23.20%
Net income/share CAGR of 23.20% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage that can expand mid-term.
-9.07%
Negative 3Y CAGR while Medical - Pharmaceuticals median is 7.03%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
341.28%
Equity/share CAGR of 341.28% while Medical - Pharmaceuticals median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
88.66%
5Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 3.23%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
40.10%
3Y equity/share CAGR > 1.5x Medical - Pharmaceuticals median of 10.86%. Joel Greenblatt sees strong short-term returns on equity fueling net worth growth.
140.00%
Dividend/share CAGR of 140.00% while Medical - Pharmaceuticals is zero. Walter Schloss sees a minor improvement that could compound if the firm maintains consistent raises.
166.67%
5Y dividend/share CAGR of 166.67% while Medical - Pharmaceuticals is zero. Walter Schloss sees at least some improvement that could compound over time.
9.09%
3Y dividend/share CAGR of 9.09% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight advantage if the firm is at least inching up payouts.
5.48%
Receivables growth far exceeding Medical - Pharmaceuticals median. Jim Chanos suspects potential red flags in revenue quality.
6.87%
Inventory growth of 6.87% while Medical - Pharmaceuticals median is zero. Walter Schloss checks if we’re preparing for a sales push or risking overstock.
0.24%
Asset growth of 0.24% while Medical - Pharmaceuticals median is zero. Walter Schloss sees a slight advantage if expansions yield good returns on capital.
2.53%
BV/share growth of 2.53% while Medical - Pharmaceuticals is zero. Walter Schloss sees a slight lead that can expand if sustained over time.
-5.67%
Debt is shrinking while Medical - Pharmaceuticals median is rising. Seth Klarman might see an advantage if growth remains possible.
No Data
No Data available this quarter, please select a different quarter.
2.76%
SG&A growth of 2.76% while Medical - Pharmaceuticals median is zero. Walter Schloss sees a modest overhead increase needing revenue justification.